Skip to main content

Table 1 Sample demographics, mean (SD)

From: Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

ADNI

 

CN Ab-/Tau-

(n=199)

CN Ab+

(n=119)

MCI Ab+

(n=97)

AD dementia

(n=59)

p-value

Age, years

70.88 (6.40)†,‡,§

74.64 (7.39)*

74.77 (7.40)*

76.20 (9.33)*

<0.001

Sex, M/F

72 / 127

44 / 75

51 / 46

31 / 28

0.011

Education, years

16.78 (2.28)§

16.68 (2.38)§

16.11 (2.46)

15.44 (2.41)*,†

<0.001

MMSE

29.19 (1.07)‡,§

28.91 (1.36)‡,§

27.49 (2.19)*,†,§

22.19 (3.96)*,†,‡

<0.001

APOE e4 carriers -/+a

136- / 51+†,‡,§

54- / 60+*

29- / 53+*

18- / 32+*

<0.001

Mean tau-PET follow-up, yearsb

1.72 (0.53)

1.64 (0.57)

1.45 (0.71)

1.37 (0.49)

0.299

BioFINDER-1

 

CN Ab-/Tau-

(n=36)

CN Ab+

(n=30)

MCI Ab+

(n=26)

AD dementia

(n=46)

p-value

Age, years

73.86 (7.27)

73.80 (7.44)

71.73 (9.72)

71.43 (7.34)

0.274

Sex, M/F

19 / 17

12 / 18

18 / 8

25 / 21

0.187

Education, years

12.42 (3.80)

11.93 (3.72)

12.21 (3.93)

12.22 (3.75)

0.928

MMSE

28.86 (1.10)‡,§

28.83 (1.15)‡,§

25.58 (3.06)*,†,§

20.96 (4.87)*,†,‡

< 0.001

APOE e4 carriers -/+

29- / 7+†,‡,§

8- / 22+*

6- / 20+*

19- / 27+*

< 0.001

Mean tau-PET follow-up, yearsc

2.03 (0.47)

1.94 (0.32)

1.82 (0.12)

1.87 (0.34)

0.470

  1. Abbreviations:  Amyloid-beta, AD Alzheimer’s disease, APOE Apolipoprotein E, CN Cognitively normal, F Female, M Male, MCI Mild cognitive impairment, MMSE Mini-Mental State Exam
  2. aavailable for 187 CN Aβ-/Tau-, 114 CN Aβ+, 82 MCI Aβ+, and 50 AD dementia
  3. bsubsample of 35 CN Aβ-/Tau-, 60 CN Aβ+, 39 MCI Aβ+, and 24 AD dementia
  4. csubsample of 16 CN Aβ-/Tau-, 14 CN Aβ+, 7 MCI Aβ+, and 18 AD dementia
  5. *Significantly different from CN Aβ-/Tau-
  6. Significantly different from CN Aβ+
  7. Significantly different from MCI Aβ+
  8. §Significantly different from AD dementia (significant after applying a Bonferroni-corrected α-threshold of 0.0125)